Achieving Efficacy With Second TNFi in RA After Primary TNFi Failure

RA in hand
RA in hand
Data from this trial suggest that immediately switching from one tumor necrosis factor (TNF) inhibitor to another inhibitor was safe in those who had primary TNFi failure, even without a drug washout period.

Roy Fleischmann, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center, discusses with Rheumatology Advisor results from the EXXELERATE trial (Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Inadequately Responding to Methotrexate; ClinicalTrials.gov Identifier: NCT01500278).

Data from this trial suggest that immediately switching from one tumor necrosis factor (TNF) inhibitor to another inhibitor was safe in those who had primary TNFi failure, even without a drug washout period.

Related Articles

Reference

Fleischmann R, Burmester GR, Combe B, et al. Efficacy and safety of switching between certolizumab pegol and adalimumab after primary anti-TNF treatment failure: 2-Year results from a randomized, investigator-blind, superiority head-to-head study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/efficacy-and-safety-of-switching-between-certolizumab-pegol-and-adalimumab-after-primary-anti-tnf-treatment-failure-2-year-results-from-a-randomized-investigator-blind-superiority-head-to-head-stud/. Accessed November 28, 2016.

follow @RheumAdvisor